• To assess the potential short- and long-term efficacy of phenytoin in treating recessive dystrophic epidermolysis bullosa (RDEB), we treated 22 patients with therapeutic doses of oral phenytoin (blood level, 8 to 10 μg/mL for periods ranging from eight to 99 weeks. Fourteen (64%) of the 22 patients had greater than a 40% mean percentage decrease in blistering of the skin. Nine (41%) of the 22 patients were treated for longer than 75 weeks, and seven (78%) of these nine patients had a mean decrease in blistering of at least 40% during phenytoin therapy. These data, along with previous reports, suggest that phenytoin has therapeutic efficacy in RDEB.
(Arch Dermatol 1984;120:490-495)
Cooper TW, Bauer EA. Therapeutic Efficacy of Phenytoin in Recessive Dystrophic Epidermolysis: A Comparison of Short- and Long-term Treatment. Arch Dermatol. 1984;120(4):490–495. doi:10.1001/archderm.1984.01650400072015
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.